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Abstract 
Background: Meningeal hemangiopericytoma is a rare, aggressive CNS tumor that tends to 
invade locally, metastasize, and has a high rate of recurrence. HIV classically increases the 
risk of 3 AIDS-defining malignancies: Kaposi’s sarcoma, non-Hodgkin’s lymphoma and 
invasive cervical cancer. More recently, considerable interest has been paid to the link 
between HIV and a wider range of non-AIDS-defining cancers. An HIV-positive patient with 
meningeal hemangiopericytoma is described.  
Case Description: A 36-year-old HIV-positive male presented with worsening headache and 
ataxia. The patient had experienced similar neurologic symptoms 4 months prior and MRI at 
that time had showed an extra-axial left cerebellar mass most consistent with benign 
meningioma. Repeat MRI showed the tumor had increased in size by a factor of greater than 
20 in this 4-month period, with 4 small additional foci of similar enhancement. Subtotal 
resection was performed on the mass and final pathological diagnosis was meningeal 
hemangiopericytoma.  
Conclusions: This represents the first reported case of meningeal hemangiopericytoma in an 
HIV-positive patient. This is also the shortest time to intracranial metastasis ever reported 
for a meningeal hemangiopericytoma. Although the increased risk in the HIV-positive 
population of non-AIDS-defining cancers that has been observed in recent years can largely 
be attributed to cancers with a known viral pathogenesis, it is speculated that HIV infection 
in this patient may have contributed to the occurrence or unique behavior of this rare 
tumor. 
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Introduction 
Meningeal hemangiopericytoma is a rare, aggressive CNS tumor accounting for 2.5% 
of all meningeal tumors and 1% of intracranial tumors as a whole [1]. It was initially 
considered to be a subset of meningioma but, in 1993, was reclassified as a separate 
entity by the World Health Organization [1]. Hemangiopericytoma can be clinically 
distinguished from meningioma based on its tendency to invade locally, metastasize, 
and recur [2, 3]. Metastasis tends to be extraneural and recurrence rates can reach as 
high as 92% at 15 years [1]. To our knowledge, this is the first report of a meningeal 
hemangiopericytoma in an HIV-positive patient. Additionally, this represents the 
shortest time to intracranial metastasis ever reported in a meningeal 
hemangiopericytoma. 
Case Report 
History and Diagnosis 
A 36-year-old HIV-positive male was admitted to our institution due to a 2-week history of 
worsening headache and ataxia. He was originally diagnosed with HIV 8 months prior and had begun 
antiretroviral therapy at that time, including a non-nucleoside reverse transcriptase inhibitor, 
efavirenz. Then, 4 months prior to this admission, the patient had experienced progressive ataxia and 
lower extremity paresthesias eventually leading to a brain MRI which showed an avidly enhancing 
extra-axial left cerebellar mass (fig. 1a) most consistent with benign meningioma. CD4+ count at that 
time was 44. No mass effect was noted and watchful waiting was elected at that time. The patient’s 
symptoms were stable until the clinical decline preceding this most recent admission. Repeat MRI at 
this time showed that the cerebellar mass had expanded over a period of 4 months from 1.6 × 1.6 × 
1.5 cm to 4.8 × 4.4 × 4.0 cm with effacement of the 4th ventricle, obstructive hydrocephalus, and 
additional small foci of similar enhancement located extra-axially at distant but still intracranial sites 
(fig. 1b, c). It was presumed that these additional foci represented spread of the primary process. At 
this point, the lesions were suspicious for atypical meningioma or hemangiopericytoma, primary CNS 
lymphoma, or infectious etiologies. Serum was negative for toxoplasma IgG. Cerebrospinal fluid was 
negative for Epstein-Barr virus and cytomegalovirus by polymerase chain reaction. Aerobic, 
anaerobic, fungal, viral, and acid-fast bacilli cultures of the cerebrospinal fluid were all negative. 
Operation 
The patient was brought to surgery to excise the tumor due to rapid enlargement and mass effect. 
Following posterior fossa craniotomy and microscope-aided cerebellar dissection, the tumor was 
identified as a rubbery yellow mass. Intra-operative frozen section specimens were labelled 
meningioma or hemangiopericytoma. Subtotal resection was then performed as the tumor was found 
to be extending through the tentorium. It was felt that adequate debulking had been performed 
despite leaving a small amount of residual tumor above the tentorium. 
Histopathological Findings and Postoperative Course 
Examination of the permanent sections showed a densely cellular neoplasm comprised of spindle 
cells arranged in a solid and storiform pattern. The background blood vessels had a distinct staghorn-
like pattern. Based on these features, the final diagnosis was hemangiopericytoma. The additional foci 
observed radiographically were not biopsied but were presumed to be metastases from the primary 
lesion. Following the surgery, the patient’s neurologic symptoms were stable and the extra-
ventricular drain was able to be removed on postoperative day 6. On postoperative day 10, the patient 
was discharged to a neurologic rehabilitation facility and after a short stay was discharged home. The 
patient underwent postoperative radiation therapy but, unfortunately, experienced a large recurrence 
of the cerebellar mass that required further surgery as well as interval increase in size in the 
accessory foci. The patient was undergoing additional rehabilitation at the time of submission of this 
work.  
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Discussion 
Meningeal hemangiopericytoma is a rare CNS tumor characterized by its local 
aggressiveness and tendency to recur and metastasize. In the largest published review 
of meningeal hemangiopericytoma, including follow-up data on 277 patients, local 
recurrence was seen in 57% of patients and metastasis was seen in 27% [3]. What 
makes the tumor seen in our patient unique is the speed and location of its metastases. 
Metastases of meningeal hemangiopericytoma typically take years to develop and 
spread to extra-neural sites in the vast majority of cases [2, 4]. In 2 large case series, the 
average time from initial excision to extraneural metastasis was 99 and 131 months, 
and only 1/10 and 2/10 of patients with metastasis, respectively, had spread to 
intracranial sites [1, 5]. As for intracranial metastases specifically, they have been 
observed between 9 and 15 years after the initial excision and have either been 
concurrent with or following local recurrence in 3 cases for which these data are 
reported [1, 6]. In our case, metastasis was intracranial and occurred within a period of 
4 months, making this the shortest time to intracranial metastasis ever reported. Had 
initial cranial imaging been delayed by a matter of weeks, it is likely that this would 
have instead been a presentation of a multifocal primary meningeal 
hemangiopericytoma, which has never been reported in the literature [6]. Admittedly, 
without biopsy it is impossible to be certain that these additional small foci do in fact 
represent metastases, especially considering the numerous potential etiologies of CNS 
lesions seen with HIV. Although CNS lesions of multiple distinct etiologies in a single 
patient can occur with HIV, this is seen in a small proportion of patients – 6% in 1 case 
series of stereotactic brain biopsies in patients with HIV [7]. It is therefore reasonable 
to assume that these foci represent metastases of the primary lesion based on similar 
radiographic appearance. 
Naturally, the question arises as to whether HIV infection was related to the genesis 
or uniquely aggressive behavior of this tumor. There is no known link between HIV 
infection and meningeal hemangiopericytoma, although there have been cases reported 
of non-meningeal hemangiopericytoma in HIV-positive patients [8, 9]. HIV infection is 
classically associated with an increased risk for three AIDS-defining malignancies, these 
being Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and invasive cervical cancer [10]. 
These three malignancies have an identified viral pathogenesis and, as would be 
expected intuitively, the incidence and mortality of these malignancies in the HIV-
positive population has decreased dramatically in the era of highly active antiretroviral 
therapy (HAART) [11, 12]. Although HAART has pushed the available follow-up period 
for HIV-positive patients from years to decades, an increased incidence in many non-
AIDS-defining cancers (NADCs) has been uncovered [11, 12]. The standardized 
incidence ratio (SIR) for NADCs was observed to be as high as 2.49 in the HIV-positive 
population between 2002 and 2007 [12]. In addition to impaired defense against 
oncogenic viruses, this phenomenon has been proposed to involve impaired immune 
surveillance and even HAART itself (specifically non-nucleoside reverse transcriptase 
inhibitors, which the patient in our case was treated with) [11, 12]. Meningeal 
hemangiopericytoma is so rare that a modest SIR such as 2.49 with HIV would not 
reveal itself with any statistical certainty without an incredibly large sample size. That 
being said, it is not unreasonable to entertain the possibility that HIV infection could be 
responsible for an increased risk or the accelerated growth of a rare tumor like  
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meningeal hemangiopericytoma, but we simply lack the statistical power to show that 
link conclusively. 
Of course it could be pure coincidence that this extraordinarily aggressive example 
of an already rare and aggressive tumor occurred in an HIV-positive patient. The 
elevated relative risk for NADCs that has been observed with HIV infection is due 
primarily to only a handful of cancers [12]. Two NADCs with the most consistently 
observed statistically significant risk increase with HIV infection are Hodgkin’s 
lymphoma and anal cancer [11, 12]. These two cancers have an identified viral 
pathogenesis, a trait they share with the AIDS-defining cancers. If cancers with a known 
viral pathogenesis are excluded, the increased risk of NADCs among those with HIV is 
much less striking. For example, the aforementioned SIR of 2.49 for all NADCs in the 
years 2002–2007 was calculated from an HIV-positive study cohort with 88 observed 
NADCs versus an expected incidence of 35.29 based on age- and sex-adjusted rates in 
the general population. Of these 88 NADCs, 46 were either Hodgkin’s lymphoma or anal 
cancer [12]. Excluding observed and expected incidences of these two cancers, the SIR 
for NADCs drops from 2.49 to 1.22. Additionally, other cancers contributing heavily to 
the remaining increased observed rate of NADCs include lung cancer and cancers of the 
head and neck, cancers that are strongly linked to cigarette smoking. Smoking rates are 
exceptionally high among those with HIV, as high as 51% [13], likely accounting for 
much of this remaining risk increase [11]. Thus impaired resistance to oncogenic 
viruses likely remains by far the most significant cause of increased cancer risk by HIV 
infection. Since there is no known link between meningeal hemangiopericytoma and 
any oncogenic virus, it seems less likely that HIV imparted any increased risk of 
occurrence for the tumor encountered in our case. Additionally, the aggressive 
behavior of this tumor seems likely to be coincidental as HIV-positive patients with 
more common primary intracranial NADCs such as astrocytoma appear to have 
outcomes similar to immunocompetent patients and tumor grade does not appear to be 
related to CD4+ count [14, 15]. 
While the weight of the data from larger cohorts suggests that the influence of HIV 
infection on the incidence or behavior of NADCs that lack a known viral pathogenesis is 
not clinically significant [11, 12], cases such as this one call this conclusion into 
question. To dismiss the extraordinary aggressiveness of this tumor as merely 
coincidental to HIV infection due to a lack of precedent seems irresponsible. Our 
understanding of the relationship between HIV and cancer is far from complete and will 
continue to evolve as follow-up of HIV-positive patients is increasingly measured in 
decades instead of years. This case is a perfect example of why this relationship 
deserves further inquiry. 
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Fig. 1. Coronal T1-weighted contrast-enhanced MR images. a Image obtained 4 months prior to 
admission shows an avidly enhancing extra-axial left cerebellar mass. b Image obtained shortly after 
admission shows dramatic growth of the left cerebellar mass. c Same study as in b; this image shows 
an additional small nodular extra-axial mass of similar contrast enhancement to the primary lesion 
(arrow). 
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